Steven Keith Burke
CIK 1619834 · SVP, Chief Medical Officer · last filed 2026-09-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AKBA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
180 THIRD AVENUE, FLOOR 2
WALTHAM, MA 02451
Holdings By Company
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| PRTO | Direct | 2,731 | 80.6% | 2019-03-18 |
| See footnote | 658 | 19.4% | 2019-03-18 | |
| Total | 3,389 |
10b5-1 Trading Plans
1 plan · 1 in force| Company | Adopted | Sales Can Start | Ends | Plan Allows | Sold So Far | Status | Link |
|---|---|---|---|---|---|---|---|
| AKBA Senior Vice President, Research & Development and Chief Medical Officer |
Nov 17, 2023 | Mar 16, 2024 | — | — | 125,308 last filed Feb 4, 2026 |
Active | 10-K |
Recent Filings · Page 5 of 5
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-12-06 | PRTO | Gift (G) | −2,500 | $0 | EDGAR |
| 2015-12-10 | PRTO | Grant (A) | — | $0 | EDGAR |
| 2015-07-08 | PRTO | Grant (A) | +2,403 | $21.2K | EDGAR |
| 2015-01-08 | PRTO | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).